Post-Marketing Safety of Ustekinumab Based on 14-Year Follow-Up in Danish National Patient Data.

ABSTRACT:

Purpose

Psoriasis (PsO), a chronic inflammatory skin disorder affecting a substantial proportion of populations globally, often necessitates systemic treatment including biologics. This 14-year cohort study, based on Danish national register data, aimed to investigate the enduring safety profile of ustekinumab compared to other systemic psoriasis treatments.

Methods

Using comprehensive Danish national register data, this study scrutinized patients diagnosed with psoriasis or psoriatic arthritis (PsA) who received ustekinumab. The treatment group comparators were non-biological systemic treatment (non-biologic), tumor necrosis factor α inhibitor medicine groups (TNF-α), interleukin (IL)-17 inhibitors (IL-17), and IL-23 inhibitors (IL-23). The study periods for comparisons wer

SUBMITTER: Kim S 

PROVIDER: S-EPMC11599636 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature